Clinical trial
A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
NCT07803744 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 11, 2026
- Completion date
- December 31, 2026
- Enrollment
- 18 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.